Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Proactively manage your pharmacy inventory
Anticipate generic drug launch
Manage your formulary budget
Drug patents …
… from Kazakhstan to Kalamazoo
Find generic entry opportunities
|Title:||Self-adhesive device for the percutaneous administration of an active ingredient|
|Abstract:||The present invention relates to a novel self-adhesive matrix for the percutaneous administration of an active ingredient. This matrix comprises a combination of the following: (a) 40 to 60 parts by weight of an ethylene/vinyl acetate copolymer material, (b) 40 to 60 parts by weight of a higher aliphatic monoalcohol compound, (c) 1 to 20 parts by weight of a cellulose derivative material, (d) 0.1 to 8 parts by weight of a polyhydric alcohol compound, and (e) 0.01 to 10 parts by weight of an active ingredient which can be administered percutaneously, the weight ratio a+c/b+d being between 0.7 and 1.3.|
|Inventor(s):||Guillemet; Alain (Dijon, FR), Teillaud; Eric (Talant, FR), Reginault; Philippe (Fontaine les Dijon, FR)|
|Assignee:||Laboratories D'Hygiene et de Dietetique (Paris, FR)|
Patent Claim Types:|
see list of patent claims
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|France||87 04133||Mar 25, 1987|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|European Patent Office||0288336||► subscribe|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.